<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0230">
 <label>45</label>
 <element-citation publication-type="journal" id="rf0220">
  <person-group person-group-type="author">
   <name>
    <surname>Resch</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Sommer</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Nuijten</surname>
    <given-names>M.J.</given-names>
   </name>
   <name>
    <surname>Seidinger</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Walter</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Schoellbauer</surname>
    <given-names>V.</given-names>
   </name>
  </person-group>
  <article-title>Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria</article-title>
  <source>Pediatr Infect Dis J</source>
  <volume>31</volume>
  <issue>1</issue>
  <year>2012</year>
  <fpage>e1</fpage>
  <lpage>e8</lpage>
  <ext-link ext-link-type="uri" xlink:href="pmid:21960187" id="ir0300" xmlns:xlink="http://www.w3.org/1999/xlink">21960187</ext-link>
  <pub-id pub-id-type="pmid">21960187</pub-id>
 </element-citation>
</ref>
